

Special Issue

Emerging Therapies in Renal Cell Carcinoma

Message from the Guest Editors

Therapy for renal cell carcinoma has evolved rapidly in the last decade with the development of modern immune-oncology (IO) agents and second-generation tyrosine kinase inhibitors (TKI). Combinations of these agents have emerged as standard of care front line treatment for patients with metastatic clear cell histology. Adjuvant IO therapy has now emerged as an option for high-risk localized patients after surgery. The role of cytoreductive nephrectomy has been called into question, but the role of cytoreductive nephrectomy, metastasectomy, ablative techniques, and radiation continue to play important roles in select patients. Therapeutic options are also advancing for patients with non-clear cell histologies. For the first time patients with hereditary cancer syndrome, Von Hippel Lindau, have an approved therapeutic option. We are pleased to invite you to contribute to this special issue focused on the multitude of therapeutic advances in renal cell carcinoma (RCC). For further reading, please, visit the [Special Issue website](#)

Guest Editors

Dr. Matthew T Campbell

Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Tian Zhang

Hematology and Oncology Division, Department of Internal Medicine, University of Texas Southwestern (UTSW), Dallas, TX, USA

Deadline for manuscript submissions

closed (31 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/111992

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)